Publications
Detailed Information
α-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease : alpha-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hong Jai | - |
dc.contributor.author | Park, Hee Ho | - |
dc.contributor.author | Sohn, Youngsoo | - |
dc.contributor.author | Ryu, Jina | - |
dc.contributor.author | Park, Ju Hyun | - |
dc.contributor.author | Rhee, Won Jong | - |
dc.contributor.author | Park, Tai Hyun | - |
dc.date.accessioned | 2017-04-21T02:30:04Z | - |
dc.date.available | 2017-05-04T17:42:47Z | - |
dc.date.created | 2018-07-09 | - |
dc.date.issued | 2016-12 | - |
dc.identifier.citation | Applied Microbiology and Biotechnology, Vol.100 No.24, pp.10395-10402 | - |
dc.identifier.issn | 0175-7598 | - |
dc.identifier.uri | https://hdl.handle.net/10371/116994 | - |
dc.description.abstract | Fabry disease is a genetic lysosomal storage disease caused by deficiency of alpha-galactosidase, the enzyme-degrading neutral glycosphingolipid that is transported to lysosome. Glycosphingolipid accumulation by this disease causes multi-organ dysfunction and premature death of the patient. Currently, enzyme replacement therapy (ERT) using recombinant alpha-galactosidase is the only treatment available for Fabry disease. To maximize the efficacy of treatment, enhancement of cellular delivery and enzyme stability is a challenge in ERT using alpha-galactosidase. In this study, protein nanoparticles using human serum albumin (HSA) and 30Kc19 protein, originating from silkworm, were used to enhance the delivery and intracellular alpha-galactosidase stability. 30Kc19-HSA nanoparticles loaded with the alpha-galactosidase were formed by desolvation method. 30Kc19-HSA nanoparticles had a uniform spherical shape and were well dispersed in cell culture media. 30Kc19-HSA nanoparticles had negligible toxicity to human cells. The nanoparticles exhibited enhanced cellular uptake and intracellular stability of delivered alpha-galactosidase in human foreskin fibroblast. Additionally, they showed enhanced globotriaosylceramide degradation in Fabry patients' fibroblasts. It is expected that 30Kc19-HSA protein nanoparticles could be used as an effective tool for efficient delivery and enhanced stability of drugs. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Springer Verlag | - |
dc.title | α-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease | - |
dc.title.alternative | alpha-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 이홍재 | - |
dc.contributor.AlternativeAuthor | 박희호 | - |
dc.contributor.AlternativeAuthor | 손영수 | - |
dc.contributor.AlternativeAuthor | 류지나 | - |
dc.contributor.AlternativeAuthor | 박주현 | - |
dc.contributor.AlternativeAuthor | 이원종 | - |
dc.contributor.AlternativeAuthor | 박태현 | - |
dc.identifier.doi | 10.1007/s00253-016-7689-z | - |
dc.citation.journaltitle | Applied Microbiology and Biotechnology | - |
dc.identifier.wosid | 000388955500014 | - |
dc.identifier.scopusid | 2-s2.0-84976416025 | - |
dc.description.srnd | OAIID:RECH_ACHV_DSTSH_NO:T201623719 | - |
dc.description.srnd | RECH_ACHV_FG:RR00200001 | - |
dc.description.srnd | ADJUST_YN: | - |
dc.description.srnd | EMP_ID:A002014 | - |
dc.description.srnd | CITE_RATE:3.376 | - |
dc.description.srnd | FILENAME:4. (2016.12) α-Galactosidase delivery using 30Kc19-human serum 100, 24, pp 10395–10402.pdf | - |
dc.description.srnd | DEPT_NM:화학생물공학부 | - |
dc.description.srnd | EMAIL:thpark@snu.ac.kr | - |
dc.description.srnd | SCOPUS_YN:Y | - |
dc.description.srnd | FILEURL:https://srnd.snu.ac.kr/eXrepEIR/fws/file/80bea00f-7c1b-4bdd-9406-a5c4cb7384d5/link | - |
dc.description.srnd | CONFIRM:Y | - |
dc.citation.endpage | 10402 | - |
dc.citation.number | 24 | - |
dc.citation.startpage | 10395 | - |
dc.citation.volume | 100 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Park, Tai Hyun | - |
dc.identifier.srnd | T201623719 | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | HAMSTER OVARY CELLS | - |
dc.subject.keywordPlus | SILKWORM HEMOLYMPH | - |
dc.subject.keywordPlus | RECOMBINANT PROTEIN | - |
dc.subject.keywordPlus | AGALSIDASE-ALPHA | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | SYSTEM | - |
dc.subject.keywordPlus | BETA | - |
dc.subject.keywordPlus | ENHANCEMENT | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordAuthor | Fabry disease | - |
dc.subject.keywordAuthor | Enzyme replacement therapy | - |
dc.subject.keywordAuthor | Protein nanoparticle | - |
dc.subject.keywordAuthor | Drug delivery | - |
dc.subject.keywordAuthor | Enzyme stability | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.